Drug Profile
Bivalirudin - The Medicines Company
Alternative Names: Angiomax; Angiomax RTU; Angiox; BG-8967; Hirulog-1Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer The Medicines Company
- Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Peptide fragments; Recombinant proteins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute coronary syndromes; Heparin-induced thrombocytopenia and thrombosis syndrome; Thrombosis; Unstable angina pectoris
- Discontinued Myocardial infarction
Most Recent Events
- 24 May 2023 MAIA Pharmaceuticals enters into a distribution agreement with Endo Ventures to distribute bivalirudin injection in ready-to-use vials in USA
- 15 Dec 2022 3739403: No update
- 12 May 2022 Updated efficacy data from a phase III BRAVO2/3 trial in Thrombosis prevention presented at the 71st Annual Scientific Session of the American College of Cardiology (ACC-2022)